Subscribe
16 October 2017Americas

Tribe defends Allergan deal in letter to senators

The Saint Regis Mohawk Tribe has launched a fierce defence of its patent licensing deal with Allergan, giving the Senate Judiciary Committee six main reasons which justify the agreement.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Allergan documents due to address patent ‘sham’ question
12 October 2017   Allergan has until tomorrow, Friday October 13, to address the question of whether its patent licensing deal with a Native American tribe was a sham.
Americas
Tribe ‘outraged’ at bill seeking to revoke IPR immunity
6 October 2017   The Saint Regis Mohawk Tribe has said it is “outraged” by proposed legislation introduced by Senator Claire McCaskill aimed at tackling sovereign immunity.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

AIPPI: Personalised medicine tests the limits in patent law
Ropes & Gray loses 21-attorney group to join rival on growth spree
How 'Boehringer' sets preliminary relief threshold for generics
‘Whose trademark law is AI based on exactly?’: Key questions from Marques
The Quintara decision: Defining trade secrets in federal cases
To disclose or not: Pharma patents face new AI reality
Trade secrets go global: How brand owners face a high-stakes battlefront
Killing the golden goose of US drug innovation (Part II): Drug pricing myths